According to the recently updated KDIGO guidelines [27] for the management of chronic kidney disease, SGLT2 inhibitors are strongly recommended for the treatment of CKD patients with UACR >200 mg/g. This evidence concerns the gene SLC5A2 and chronic kidney disease.